
Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).

Published: July 10th 2015 | Updated: October 7th 2020